Small Cap Losers: PRLD, ORIC, FMTX
3:42 pm Thursday, October 07th, 2021
Prelude Therapeutics Inc (NASDAQ:PRLD) announced its presentation of data from several pipeline programs, including from the dose escalation portions of co’s Phase 1 trials of oral PRMT5 inhibitors PRT543 and PRT811 and preclinical data for CDK9 inhibitor PRT2527, at the AACR-NCI-EORTC Conference. Co stated that PRT543 and PRT811 demonstrated “favorable safety profiles, dose-dependent increases in pharmacokinetic parameters, target engagement, and achieved degrees of PRMT5 inhibition required for efficacy in preclinical models at well tolerated doses.” Falls to new lows.
ORIC Pharmaceuticals Inc (NASDAQ:ORIC) trades at record lows after providing data updates from its Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide as well as preclinical data for ORIC-114 for presentation at the AACR-NCI-EORTC Conference.
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) presented initial clinical data from the Phase 1 Courage Study of FT-7051 in men with metastatic castration-resistant prostate cancer at the AACR-NCI-EORTC Conference. Among results, initial pharmacokinetic analysis of FT-7051 demonstrated rapid absorption; skin biopsies of participants demonstrated a reduction in H3K27AC, a marker of activity in the CBP/p300 pathway, the target of FT-7051. One patient experienced Grade 3 hyperglycemia; dose escalation is ongoing.
